SynthesisThe Lancet. Infectious diseases2019
The global burden of non-typhoidal salmonella invasive disease: a systematic analysis for the Global Burden of Disease Study 2017.
Synthesis in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 380 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
380 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Invasive non-typhoidal Salmonella infections in China (1961-2024): a retrospective systematic analysis of multicentre case reports.Journal of global health · 2026Pooled it
- Length of hospital stay and associated treatment costs for patients with susceptible and antibiotic-resistantBMJ open · 2025Pooled it
- Nationwide trends and features of human salmonellosis outbreaks in China.Emerging microbes & infections · 2024Pooled it
- Pooled it
- Prevalence and distribution of non-typhoidalEpidemiology and infection · 2023Pooled it
- Safety and Immunogenicity of a Trivalent Salmonella Conjugate Vaccine to S. Typhi, S. Typhimurium, and S. Enteritidis.The Journal of infectious diseases · 2026Trial
- Safety and immunogenicity of the invasive non-typhoidal Salmonella (iNTS)-GMMA vaccine: a first-in-human, randomised, dose escalation trial.EBioMedicine · 2025Trial
- Article
- Recent developments in typhoidal and non-typhoidal Salmonella vaccines.Current opinion in infectious diseases · 2026Review
- Multi-Omics and Functional Analysis ofToxins · 2026Article
- Invasive Non-typhoidalInfectious diseases & clinical microbiology · 2026Article
- Global Genomic Analysis Reveals Spatial Patterns and Temporal Trends of Priority-Antimicrobial Resistance inVeterinary sciences · 2026Article
- Global genomic surveillance uncovers emergence and spatiotemporal patterns of World Health Organization priority antibiotic resistance in invasive Salmonella.Nature communications · 2026Article
- Direct Hospitalization Costs Associated with Resistant and SusceptibleFoodborne pathogens and disease · 2026Article
- Global genomic surveillance ofmBio · 2026Article
- Prevalence, serotype diversity, and antibiotic resistance of non-typhoidal Salmonella in East African poultry: A systematic review and meta-analysis.Poultry science · 2026Article
- Pan genome clustering identifies a novel mosaic prophage specific to Salmonella Enteritidis lineage associated with the invasive disease in India.PLoS neglected tropical diseases · 2026Article
- Public health data collected by PulseNet support a role forMicrobiology spectrum · 2026Article
- Clinical characteristics and risk factor analysis of invasive non-typhoidal Salmonella infection in children.Gut pathogens · 2026Article
- An inflammasome-driven differentiation program in intestinal stem cells protects against Salmonella infection.Nature immunology · 2026Article
320 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
1 author.
Funding
Abstract
backgroundNon-typhoidal salmonella invasive disease is a major cause of global morbidity and mortality. Malnourished children, those with recent malaria or sickle-cell anaemia, and adults with HIV infection are at particularly high risk of disease. We sought to estimate the burden of disease attributable to non-typhoidal salmonella invasive disease for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017.
methodsWe did a systematic review of scientific databases and grey literature, and estimated non-typhoidal salmonella invasive disease incidence and mortality for the years 1990 to 2017, by age, sex, and geographical location using DisMod-MR, a Bayesian meta-regression tool. We estimated case fatality by age, HIV status, and sociodemographic development. We also calculated the HIV-attributable fraction and estimated health gap metrics, including disability-adjusted life-years (DALYs).
findingsWe estimated that 535 000 (95% uncertainty interval 409 000-705 000) cases of non-typhoidal salmonella invasive disease occurred in 2017, with the highest incidence in sub-Saharan Africa (34·5 [26·6-45·0] cases per 100 000 person-years) and in children younger than 5 years (34·3 [23·2-54·7] cases per 100 000 person-years). 77 500 (46 400-123 000) deaths were estimated in 2017, of which 18 400 (12 000-27 700) were attributable to HIV. The remaining 59 100 (33 300-98 100) deaths not attributable to HIV accounted for 4·26 million (2·38-7·38) DALYs in 2017. Mean all-age case fatality was 14·5% (9·2-21·1), with higher estimates among children younger than 5 years (13·5% [8·4-19·8]) and elderly people (51·2% [30·2-72·9] among those aged ≥70 years), people with HIV infection (41·8% [30·0-54·0]), and in areas of low sociodemographic development (eg, 15·8% [10·0-22·9] in sub-Saharan Africa).
interpretationWe present the first global estimates of non-typhoidal salmonella invasive disease that have been produced as part of GBD 2017. Given the high disease burden, particularly in children, elderly people, and people with HIV infection, investigating the sources and transmission pathways of non-typhoidal salmonella invasive disease is crucial to implement effective preventive and control measures.
fundingBill & Melinda Gates Foundation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.